Evidence map›Paper›PMID 25276134›Full record

ReviewJournal of oncology2014

Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.

Nicole Pinto, Morgan Black, Krupal Patel, John Yoo, Joe S Mymryk, John W Barrett, Anthony C Nichols

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Introduction and expression of PIK3CAJournal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Nicole PintoDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7.ORCID 0000-0001-5306-7186
Morgan BlackDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7.ORCID 0000-0002-2762-1937
Krupal PatelDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7.
John YooDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7 ; London Regional Cancer Program, London, ON, Canada N6C 2R6 ; Department of Oncology, The University of Western Ontario, London, ON, Canada N6A 3K7.ORCID 0000-0002-2815-893X
Joe S MymrykLondon Regional Cancer Program, London, ON, Canada N6C 2R6 ; Department of Oncology, The University of Western Ontario, London, ON, Canada N6A 3K7 ; Lawson Health Research Institute, London, ON, Canada N6C 2R5 ; Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada N6A 3K7.
John W BarrettDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7 ; London Regional Cancer Program, London, ON, Canada N6C 2R6 ; Department of Oncology, The University of Western Ontario, London, ON, Canada N6A 3K7 ; Lawson Health Research Institute, London, ON, Canada N6C 2R5.
Anthony C NicholsDepartment of Otolaryngology, Head & Neck Surgery, The University of Western Ontario, London, ON, Canada N6A 3K7 ; London Regional Cancer Program, London, ON, Canada N6C 2R6 ; Department of Oncology, The University of Western Ontario, London, ON, Canada N6A 3K7 ; Lawson Health Research Institute, London, ON, Canada N6C 2R5 ; Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada N6A 3K7.
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid cancer is an endocrine malignancy with an incidence rate that has been increasing steadily over the past 30 years. While well-differentiated subtypes have a favorable prognosis when treated with surgical resection and radioiodine, undifferentiated subtypes, such as anaplastic thyroid cancer (ATC), are far more aggressive and have a poor prognosis. Conventional therapies (surgical resection, radiation, chemotherapy, and radioiodine) have been utilized for treatment of ATC, yet these treatments have not significantly improved the overall mortality rate. As cancer is a genetic disease, genetic alterations such as mutations, fusions, activation of oncogenes, and silencing of tumor suppressors contribute to its aggressiveness. With the use of next-generation sequencing and the Cancer Genome Atlas, mutation-directed therapy is recognized as the upcoming standard of care. In this review, we highlight the known genetic landscape of ATC and the need for a comprehensive genetic characterization of this disease in order to identify additional therapeutic targets to improve patient outcomes.

Identifiers

PMID25276134
PMCPMC4170827
OpenAlexW2119862400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.